Protagonist Therapeutics (PTGX) EPS (Weighted Average and Diluted) (2021 - 2026)

Protagonist Therapeutics has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting $0.05 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.05, up 126.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.82 (down 333.33% YoY), and the FY2025 annual result was -$2.05, down 148.46% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.05 for Q1 2026 at Protagonist Therapeutics, up from -$0.7 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.26 in Q1 2024 to a low of -$0.84 in Q2 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.55 (2025), against an average of -$0.11.
• Across the five-year window, EPS (Weighted Average and Diluted) soared 586.57% in 2024 and sank 134.83% in 2025, its largest moves.
• Protagonist Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.7 in 2022, then soared by 174.29% to $0.52 in 2023, then surged by 286.54% to $2.01 in 2024, then tumbled by 134.83% to -$0.7 in 2025, then jumped by 107.14% to $0.05 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.05 (Q1 2026), -$0.7 (Q4 2025), and -$0.62 (Q3 2025), per Business Quant data.